Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Healthcare delivery for HIV-positive people with tuberculosis in Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiac chamber volumes and left ventricular mass in people living with HIV and matched uninfected controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Amanda Mocroft
  • Jose M Miro
  • Gilles Wandeler
  • Josep M Llibre
  • Anders Boyd
  • Kathrin van Bremen
  • Marek Beniowski
  • Julia Mikhalik
  • Matthias Cavassini
  • Fernando Maltez
  • Claudine Duvivier
  • Caterina Uberti Foppa
  • Brygida Knysz
  • Elzbieta Bakowska
  • Elena Kuzovatova
  • Pere Domingo
  • Alexandra Zagalo
  • Jean-Paul Viard
  • Olaf Degen
  • Ana Milinkovic
  • Thomas Benfield
  • Lars Peters
  • EuroSIDA study group
Vis graf over relationer

OBJECTIVES: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH).

METHODS: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit.

RESULTS: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94-8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47-12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00-1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00-1.89) and NHL (aIRR 2.57; 95% CI 1.16-5.68). There was no significant association between HBV and lung or anal cancer.

CONCLUSIONS: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.

TidsskriftHIV Medicine
Udgave nummer6
Sider (fra-til)585-598
Antal sider14
StatusUdgivet - jul. 2022

Bibliografisk note

© 2021 British HIV Association.

ID: 70534809